Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis

OncoImmunology

Volumn 6, Issue 2, 2017, Pages

  Hendrickx, Wouter ^a   Simeone, Ines ^b,c   Anjum, Samreen ^b   Mokrab, Younes ^a   Bertucci, François ^d,e,f   Finetti, Pascal ^d   Curigliano, Giuseppe ^g   Seliger, Barbara ^h   Cerulo, Luigi ^c,i   Tomei, Sara ^a   Delogu, Lucia Gemma ^j   Maccalli, Cristina ^a   Wang, Ena ^a   Miller, Lance D ^k   Marincola, Francesco M ^a   Ceccarelli, Michele ^b   Bedognetti, Davide ^a  

^a SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^b QATAR COMPUTING RESEARCH INSTITUTE   (Qatar)

^c UNIVERSITY OF SANNIO   (Italy)

^d INSTITUT PAOLI CALMETTES   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^h MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

ⁱ Grande Ospedale Metropolitano   (Italy)

^j UNIVERSITY OF SASSARI   (Italy)

^k WAKE FOREST SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Breast cancer; chemokines; exome sequencing; immune checkpoint; immune signatures; immunologic constant of rejection; MAPK mutations; PD L1; predictive signatures; prognostic signatures; triple negative

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CXCR4; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA INTERFERON RECEPTOR 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 12P40; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 17C; INTERLEUKIN 17F; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 28; INTERLEUKIN 29; MACROPHAGE DERIVED CHEMOKINE; MITOGEN ACTIVATED PROTEIN KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN P53; RANTES; STAT1 PROTEIN; STAT4 PROTEIN; STROMAL CELL DERIVED FACTOR 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER IMMUNOTHERAPY; CHROMOSOME; COPY NUMBER VARIATION; GENE; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENOME ANALYSIS; IMMUNE RESPONSE; IMMUNOREGULATION; MAP2K4 GENE; MAP3K1 GENE; OVERALL SURVIVAL; PHENOTYPE; RNA SEQUENCE; SOMATIC MUTATION; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

EID: 85011817556     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1253654     Document Type: Article

References (109)

1. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours:impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245
2. Galon J, Mlecnik B, Marliot F, Ou F-S, Carlo Bruno B, Lugli A, Zlobec I, Rau TT, Hartmann A, Masucci GV, et al. Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer:Results of a worldwide consortium-based analysis of 1,336 patients. J Clin Oncol 2016.
3. Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials:ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32:2959-66; PMID:25071121; http://dx.doi.org/10.1200/JCO.2013.55.0491
4. Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Eenoo FV, Rouas G, Francis P, Crown JPA, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy:BIG 02-98. J Clin Oncol 2013; 31:860-7; PMID:23341518; http://dx.doi.org/10.1200/JCO.2011.41.0902
5. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, Kellokumpu-Lehtinen P-L, Bono P, Kataja V, Desmedt C, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer:results from the FinHER trial. Ann Oncol 2014; 25:1544-50; PMID:24608200; http://dx.doi.org/10.1093/annonc/mdu112
6. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Eynden GV den, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer:recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26:259-71; PMID:25214542; http://dx.doi.org/10.1093/annonc/mdu450
7. Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, Darb-Esfahani S, Kronenwett R, Hanusch C, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28:105-13; PMID:19917869; http://dx.doi.org/10.1200/JCO.2009.23.7370
8. Denkert C, Minckwitz G von, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2–positive and triple-negative primary breast cancers. J Clin Oncol 2015; 33:983-91; PMID:2553437; http://dx.doi.org/10.1200/JCO.2014.58.1967
9. Bedognetti D, Wang E, Sertoli MR, Marincola FM. Gene expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010; 9:555-65; PMID:20518712; http://dx.doi.org/10.1586/erv.10.55
10. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012; 131:387-95; PMID:21964766; http://dx.doi.org/10.1002/ijc.26471
11. Panelli MC, Wang E, Phan G, Puhlmann M, Miller L, Ohnmacht GA, Klein HG, Marincola FM. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002; 3:RESEARCH0035; PMID:12184809; http://dx.doi.org/10.1186/gb-2002-3-7-research0035
12. Panelli MC, Stashower ME, Slade HB, Smith K, Norwood C, Abati A, Fetsch P, Filie A, Walters S-A, Astry C, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007; 8:R8; PMID:17222352; http://dx.doi.org/10.1186/gb-2007-8-1-r8
13. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62:3581-6; PMID:12097256
14. Weiss GR, Grosh WW, Chianese-Bullock KA, Zhao Y, Liu H, Slingluff CL, Marincola FM, Wang E. Molecular insights on the peripheral and intra-tumoral effects of systemic high dose rIL-2 (Aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011; 17:7440-50; PMID:21976537; http://dx.doi.org/10.1158/1078-0432.CCR-11-1650
15. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang X-Y, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2012; 131:871-80; PMID:21479927; http://dx.doi.org/10.1007/s10549-011-1470-x
16. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
17. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance:prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008
18. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, Berger A, Bruneval P, Fridman W-H, Pagès F, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263-71; PMID:21303976; http://dx.doi.org/10.1158/0008-5472.CAN-10-2907
19. Bedognetti D, Spivey TL, Zhao Y, Uccellini L, Tomei S, Dudley ME, Ascierto ML, De Giorgi V, Liu Q, Delogu LG, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 2013; 109:2412-23; PMID:24129241; http://dx.doi.org/10.1038/bjc.2013.557
20. Ulloa-Montoya F, Louahed J, Dizier B, Gruselle O, Spiessens B, Lehmann FF, Suciu S, Kruit WHJ, Eggermont AMM, Vansteenkiste J, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013; 31:2388-95; PMID:23715562; http://dx.doi.org/10.1200/JCO.2012.44.3762
21. Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013; 31:2369-71; PMID:23715576; http://dx.doi.org/10.1200/JCO.2013.49.2157
22. Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; http://dx.doi.org/10.1038/nature14011
23. Ji R-R, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, Alaparthy S, Berman D, Jure-Kunkel M, Siemers NO, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2011; 61:1019-31; PMID:22146893; http://dx.doi.org/10.1007/s00262-011-1172-6
24. Ribas A, Robert C, Hodi FS, Wolchok JD, Joshua AM, Hwu W-J, Weber JS, Zarour HM, Kefford R, Loboda A, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J Clin Oncol 2015
25. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 2015; 350:207-11; PMID:26359337; http://dx.doi.org/10.1126/science.aad0095
26. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of the oral mucosa. Blood 2009; 113:3620-30; PMID:19168793; http://dx.doi.org/10.1182/blood-2008-07-168351
27. Saint-Mezard P, Berthier CC, Zhang H, Hertig A, Kaiser S, Schumacher M, Wieczorek G, Bigaud M, Kehren J, Rondeau E, et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int 2009; 22:293-302; PMID:19017305; http://dx.doi.org/10.1111/j.1432-2277.2008.00790.x
28. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang E, Marincola FM, et al. Gene expression profiling in acute allograft rejection:challenging the immunologic constant of rejection hypothesis. J Transl Med 2011; 9:174; PMID:21992116; http://dx.doi.org/10.1186/1479-5876-9-174
29. Yoshida S, Arakawa F, Higuchi F, Ishibashi Y, Goto M, Sugita Y, Nomura Y, Niino D, Shimizu K, Aoki R, et al. Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection:up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scand J Rheumatol 2012; 41:170-9; PMID:22401175; http://dx.doi.org/10.3109/03009742.2011.623137
30. Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B. Disentangling the relationship between tumor genetic programs and immune responsiveness. Curr Opin Immunol 2016; 39:150-8; PMID:26967649; http://dx.doi.org/10.1016/j.coi.2016.02.001
31. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity:effector response to tumour and role of the microenvironment. Lancet Lond Engl 2008; 371:771-83; PMID:18275997; http://dx.doi.org/10.1016/S0140-6736(08)60241-X
32. Wang E, Worschech A, Marincola FM. The immunologic constant of rejection. Trends Immunol 2008; 29:256-62; PMID:18457994; http://dx.doi.org/10.1016/j.it.2008.03.002
33. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5:200ra116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
34. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015; 23:32-8; PMID:26047524; http://dx.doi.org/10.1016/j.coph.2015.05.011
35. Ascierto ML, Idowu MO, Zhao Y, Khalak H, Payne KK, Wang X-Y, Dumur CI, Bedognetti D, Tomei S, Ascierto PA, et al. Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med 2013; 11:145; PMID:23758773; http://dx.doi.org/10.1186/1479-5876-11-145
36. Bedognetti D, Wang E, Marincola FM. Meta-analysis and metagenes:CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome. OncoImmunology 2014; 3:e28727; PMID:25340012; http://dx.doi.org/10.4161/onci.28727
37. Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, et al. Gene expression profiles of inflammatory breast cancer:correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol 2014; 25:358-65; PMID:24299959; http://dx.doi.org/10.1093/annonc/mdt496
38. Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SAW, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015; 21:1688-98; PMID:25208879; http://dx.doi.org/10.1158/1078-0432.CCR-14-0432
39. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14:5158-65; PMID:18698033; http://dx.doi.org/10.1158/1078-0432.CCR-07-4756
40. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, Ravoet M, Le Buanec H, Sibille C, Manfouo-Foutsop G, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873-92; PMID:23778140; http://dx.doi.org/10.1172/JCI67428
41. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes:a pooled analysis. J Clin Oncol 2012; 30:1996-2004; PMID:22508827; http://dx.doi.org/10.1200/JCO.2011.39.5624
42. Lee HJ, Lee J-J, Song IH, Park IA, Kang J, Yu JH, Ahn J-H, Gong G. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer:relationship to tumor-infiltrating lymphocytes. Breast Cancer Res Treat 2015; 151:619-27; PMID:26006068; http://dx.doi.org/10.1007/s10549-015-3438-8
43. Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, et al. Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. Cancer Immunol Res 2016; 4:600-10; PMID:27197066; http://dx.doi.org/10.1158/2326-6066
44. Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol 2015; 33:701-8; PMID:25605861; http://dx.doi.org/10.1200/JCO.2014.57.6298
45. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; http://dx.doi.org/10.1038/nm.3708
46. Stoll G, Enot D, Mlecnik B, Galon J, Zitvogel L, Kroemer G. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. OncoImmunology 2014; 3:e27884; PMID:24790795; http://dx.doi.org/10.4161/onci.27884
47. Bedognetti D, Hendrickx W, Marincola FM, Miller LD. Prognostic and predictive immune gene signatures in breast cancer. Curr Opin Oncol 2015; 27:433-44; PMID:26418235; http://dx.doi.org/10.1097/CCO.0000000000000234
48. Bedognetti D, Maccalli C, Bader SBJA, Marincola FM, Seliger B. Checkpoint inhibitors and their application in breast cancer. Breast Care (Basel) 2016; 11:108-15; PMID:27239172; http://dx.doi.org/10.1159/000445335
49. Emens LA, Braiteh FS, Cassier P, DeLord J-P, Eder JP, Shen X, Xiao Y, Wang Y, Hegde PS, Chen DS, et al. Abstract PD1-6:Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Res 2015; http://dx.doi.org/10.1158/1538-7445
50. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez EJ, et al. Abstract S1-09:A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res 2015; http://dx.doi.org/10.1158/1538-7445
51. Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 2015; 523:231-5; PMID:25970248; http://dx.doi.org/10.1038/nature14404
52. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406:536-40; PMID:10952317; http://dx.doi.org/10.1038/35020115
53. Spivey TL, De Giorgi V, Zhao Y, Bedognetti D, Pos Z, Liu Q, Tomei S, Ascierto ML, Uccellini L, Reinboth J, et al. The stable traits of melanoma genetics:an alternate approach to target discovery. BMC Genomics 2012; 13:156; PMID:22537248; http://dx.doi.org/10.1186/1471-2164-13-156
54. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348
55. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in Melanoma. N Engl J Med 2014; 371:2189-99; PMID:25409260; http://dx.doi.org/10.1056/NEJMoa1406498
56. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, et al. MYC regulates the antitumor immune response through CD47 and PD-L1. Science 2016; 352:227-31; PMID:26966191; http://dx.doi.org/10.1126/science.aac9935
57. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 2016; 6:202-16; PMID:26645196; http://dx.doi.org/10.1158/2159-8290.CD-15-0283
58. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462:108-12; PMID:19847166; http://dx.doi.org/10.1038/nature08460
59. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi.org/10.1016/j.immuni.2013.10.003
60. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61-70; PMID:23000897; http://dx.doi.org/10.1038/nature11412
61. Peddi PF, Ellis MJ, Ma C, Peddi PF, Ellis MJ, Ma C. Molecular basis of triple negative breast cancer and implications for therapy, molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2011; 2012:e217185; PMID:22295242; http://dx.doi.org/10.1155/2012/217185
62. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499:214-8; PMID:23770567; http://dx.doi.org/10.1038/nature12213
63. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446:153-8; PMID:17344846; http://dx.doi.org/10.1038/nature05610
64. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486:353-60; PMID:22722193; http://dx.doi.org/10.1038/nature11143
65. Ma CX, Ellis MJ. The Cancer Genome Atlas:clinical applications for breast cancer. Oncology (Williston Park) 2013; 27:1263-9, 1274-9; PMID:24624545.
66. Ortutay C, Vihinen M. Immunome:A reference set of genes and proteins for systems biology of the human immune system. Cell Immunol 2006; 244:87-9; PMID:17434156; http://dx.doi.org/10.1016/j.cellimm.2007.01.012
67. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 2015; 21:938-45; PMID:26193342; http://dx.doi.org/10.1038/nm.3909
68. Avalle L, Pensa S, Regis G, Novelli F, Poli V. STAT1 and STAT3 in tumorigenesis:A matter of balance. JAK-STAT 2012; 1:65-72; PMID:24058752; http://dx.doi.org/10.4161/jkst.20045
69. Koromilas AE, Sexl V. The tumor suppressor function of STAT1 in breast cancer. JAK-STAT 2013; 2:e23353; PMID:24058806; http://dx.doi.org/10.4161/jkst.23353
70. Sonnenblick A, Brohée S, Fumagalli D, Vincent D, Venet D, Ignatiadis M, Salgado R, Eynden GV, den Rothé F, Desmedt C, et al. Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Med 2015; 13:177; PMID:26234940; http://dx.doi.org/10.1186/s12916-015-0416-2
71. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity:a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809; PMID:19851315; http://dx.doi.org/10.1038/nrc2734
72. Chen DS, Mellman I. Oncology meets immunology:the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j.immuni.2013.07.012
73. Franciszkiewicz K, Boissonnas A, Boutet M, Combadière C, Mami-Chouaib F. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res 2012; 72:6325-32; PMID:23222302; http://dx.doi.org/10.1158/0008-5472.CAN-12-2027
74. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160:48-61; PMID:25594174; http://dx.doi.org/10.1016/j.cell.2014.12.033
75. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. OncoImmunology 2013; 2:e24720; PMID:24073365; http://dx.doi.org/10.4161/onci.24720
76. Tsang JYS, Ni Y-B, Chan S-K, Yamaguchi R, Tanaka M, Tan P-H, Tse GM. Increased lymphocytic infiltration in breast cancer correlated with molecular subtypes and HER2 gene amplification. Histopathology 2013; 62:963-5; PMID:23551496; http://dx.doi.org/10.1111/his.12085
77. Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem 2012; 113:433-9; PMID:22006292; http://dx.doi.org/10.1002/jcb.23400
78. Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, Denkert C, Schneeweiss A, Budczies J, Sinn P, et al. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget 2014; 5:9952-65; PMID:25296970; http://dx.doi.org/10.18632/oncotarget.2481
79. Quigley D, Silwal-Pandit L, Dannenfelser R, Langerød A, Vollan HKM, Vaske C, Siegel JU, Troyanskaya O, Chin S-F, Caldas C, et al. Lymphocyte invasion in IC10/Basal-like breast tumors is associated with Wild-type TP53. Mol Cancer Res 2015; 13:493-501; PMID:25351767; http://dx.doi.org/10.1158/1541-7786.MCR-14-0387
80. Bogoyevitch MA, Court NW. Counting on mitogen-activated protein kinases—ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 2004; 16:1345-54; PMID:15381250; http://dx.doi.org/10.1016/j.cellsig.2004.05.004
81. Shaul YD, Seger R. The MEK/ERK cascade:From signaling specificity to diverse functions. Biochim Biophys Acta–Mol Cell Res 2007; 1773:1213-26; PMID:17112607; http://dx.doi.org/10.1016/j.bbamcr.2006.10.005
82. Pavese JM, Ogden IM, Voll EA, Huang X, Xu L, Jovanovic B, Bergan RC. Mitogen-activated protein kinase kinase 4 (MAP2K4) promotes human prostate cancer metastasis. PLoS One 2014; 9:e102289; PMID:25019290; http://dx.doi.org/10.1371/journal.pone.0102289
83. Pham TT, Angus SP, Johnson GL. MAP3K1 genomic alterations in cancer and function in promoting cell survival or apoptosis. Genes Cancer 2013; (11-12):419-26; PMID:24386504; http://dx.doi.org/10.1177/1947601913513950
84. Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases—regulating the immune response. Nat Rev Immunol 2007; 7:202-12; PMID:17318231; http://dx.doi.org/10.1038/nri2035
85. Arthur JSC, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13:679-92; PMID:23954936; http://dx.doi.org/10.1038/nri3495
86. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol 2012; 32:23-63; PMID:22428854; http://dx.doi.org/10.1615/CritRevImmunol.v32.i1.30
87. Jackson AM, Mulcahy LA, Porte J, Franks HA, El Refaee M, Wang Q, Shah S, Zhu X, Patel PM. Role of mitogen-activated protein kinase and PI3K pathways in the regulation of IL-12-family cytokines in dendritic cells and the generation of T H-responses. Eur Cytokine Netw 2010; 21:319-28; PMID:21112826; http://dx.doi.org/10.1684/ecn.2010.0219
88. Soares-Silva M, Diniz FF, Gomes GN, Bahia D. The mitogen-activated protein kinase (MAPK) pathway:role in immune evasion by trypanosomatids. Front Microbiol 2016; 24;7:183; PMID:26941717; http://dx.doi.org/10.3389/fmicb.2016.00183
89. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225-31; PMID:23307859; http://dx.doi.org/10.1158/1078-0432.CCR-12-1630
90. Tomei S, Bedognetti D, De Giorgi V, Sommariva M, Civini S, Reinboth J, Al Hashmi M, Ascierto ML, Liu Q, Ayotte BD, et al. The immune-related role of BRAF in melanoma. Mol Oncol 2015; 9:93-104; PMID:25174651; http://dx.doi.org/10.1016/j.molonc.2014.07.014
91. Hu-Lieskovan S, Mok S, Moreno BH, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma. Sci Transl Med 2015; 7:279ra41-279ra41; PMID:25787767; http://dx.doi.org/10.1126/scitranslmed.aaa4691
92. Loi S. Host antitumor immunity plays a role in the survival of patients with newly diagnosed triple-negative breast cancer. J Clin Oncol 2014; 32:2935-7; PMID:25071115; http://dx.doi.org/10.1200/JCO.2014.56.7677
93. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 2016; 164:550-63; PMID:26824661; http://dx.doi.org/10.1016/j.cell.2015.12.028
94. Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM, Castiglioni I, et al. TCGAbiolinks:an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res 2016; 44:e71; PMID:26704973; http://dx.doi.org/10.1093/nar/gkv1507
95. Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 2015; 163:506-19; PMID:26451490; http://dx.doi.org/10.1016/j.cell.2015.09.033
96. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol 2013; 14:R34; PMID:23618380; http://dx.doi.org/10.1186/gb-2013-14-4-r34
97. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor:open software development for computational biology and bioinformatics. Genome Biol 2004; 5:R80; PMID:15461798; http://dx.doi.org/10.1186/gb-2004-5-10-r80
98. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8:118-27; PMID:16632515; http://dx.doi.org/10.1093/biostatistics/kxj037
99. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96; PMID:16643655; http://dx.doi.org/10.1186/1471-2164-7-96
100. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression–based predictors for breast cancer. N Engl J Med 2006; 355:560-9; PMID:16899776; http://dx.doi.org/10.1056/NEJMoa052933
101. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68; PMID:20813035; http://dx.doi.org/10.1186/bcr2635
102. Wilkerson MD, Hayes DN. ConsensusClusterPlus:a class discovery tool with confidence assessments and item tracking. Bioinformatics 2010; 26:1572-3; PMID:20427518; http://dx.doi.org/10.1093/bioinformatics/btq170
103. Abhijit. An enhanced Kaplan-Meier plot. Stat Bandit Available from:https://statbandit.wordpress.com/2011/03/08/an-enhanced-kaplan-meier-plot/
104. Robinson MD, McCarthy DJ, Smyth GK. edgeR:a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010; 26:139-40; PMID:19910308; http://dx.doi.org/10.1093/bioinformatics/btp616
105. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis:a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102:15545-50; PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102
106. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map:a network-based method for gene-set enrichment visualization and interpretation. PLoS One 2010; 5:e13984; PMID:21085593; http://dx.doi.org/10.1371/journal.pone.0013984
107. Nielsen M, Lundegaard C, Blicher T, Lamberth K, Harndahl M, Justesen S, Røder G, Peters B, Sette A, Lund O, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2007; 2:e796; PMID:17726526; http://dx.doi.org/10.1371/journal.pone.0000796
108. Shukla SA, Rooney MS, Rajasagi M, Tiao G, Dixon PM, Lawrence MS, Stevens J, Lane WJ, Dellagatta JL, Steelman S, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol 2015; 33:1152-8; PMID:26372948; http://dx.doi.org/10.1038/nbt.3344
109. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12:R41; PMID:21527027; http://dx.doi.org/10.1186/gb-2011-12-4-r41